Dr. Richard Pottorf
Chair, Department of Biology; Assistant Professor of Biochemistry
After more than 25 years of industrial experience in the pharmaceutical industry, Dr. Richard Pottorf felt the calling to give back to the field of chemistry through his education. His experience in drug discovery involved medicinal chemistry studies in cardiovascular, CNS, anti-inflammatory, and cancer therapeutic areas. He was involved in the discovery of an antihypertensive drug, Cozaar, and similar compounds. Additionally, he was involved in the discovery of preclinical compounds to treat pulmonary arterial hypertension and as anti-tumor agents. Dr. Pottorf is a co-author on more than 30 peer-reviewed scientific articles and co-inventor on several issued patents.
Dr. Pottorf and his wife reside in Indianapolis and have three grown sons, Brad, Ryan, and Andrew. They also have two grandchildren, Arabella and Caleb.
Dr. Pottorf has served at Anderson University since 2015.
BA in Chemistry, University of Northern Colorado
PhD in Biochemistry, Indiana University
Postdoctoral Fellow, University of Wisconsin–Madison
Wang, X., Inoyama, D., Russo, R., Li, S.-G., Jadhav, R., Stratton, T. P., Mittal, N., Bilotta, J. A., Singleton, E., Kim, T., Paget, S. D., Pottorf, R. S., Ahn, Y.-M., Davila-Pagan, A., Kandasamy, S., Grady, C., Hussain, S., Soteropoulos, P., Zimmerman, M. D., Ho, H. P., Park, S., Dartois, V., Ekins, S., Connell, N., Kumar, P., Freundlich, J. S. (2020). Antitubercular triazines: Optimization and intrabacterial metabolism. Cell Chem. Biol. 27, 172–185.
Allen, J. E., Kline, C. L., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Al-Mulla, F., Duvic, M., Wu, G. S., Dicker, D. T., Talekar, M. K., Lim, B., Elemento, O., Oster, W., Bertino, J., Flaherty, K., Wang, M. L., Borthakur, G., Andreeff, M., Stein, M., El-Deiry, W. S. (2016). Discovery and clinical introduction of first-in-class imipridone ONC201., Oncotarget, 7, 74380–74392.
Wagner, J., Kline, C. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Dicker, D. T., Allen, J. E., El-Deiry, W. S. (2014). The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget, 5, 12728–12737.
Ekins, S., Pottorf, R. S., Reynolds, R. C., Williams, A. J., Clark, A. M., Freundlich, J. S. (2014). Looking back to the future: Predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis. J. Chem. Inf. Model, 54, 1070–1082.